Bristol-Myers invites J&J into an alliance of giants on cardio drug development/commercialization program
J&J $JNJ has jumped into a partnership with Bristol-Myers Squibb $BMY on an early-stage cardio drug.
In an unusual alliance of giants, J&J is paying an unspecified amount of cash to partner with Bristol-Myers on BMS-986177, a Factor XIa inhibitor being developed as an anticoagulant to prevent thrombotic events.
The pharma players plan to jointly commit cash and expertise to a “broad” development program covering multiple indications and then share any profits that come out of the work. And they’re working on observations that beating back the level of thrombin can reduce the risk of heart attack, stroke and peripheral artery disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.